A case for the adoption of pharmacoeconomic guidelines in Japan

Shunya Ikeda, Naoki Ikegami, Adam J. Oliver, Mie Ikeda

研究成果: Short survey査読

16 被引用数 (Scopus)

抄録

In recent years, more and more Japanese pharmaceutical companies have been submitting pharmacoeconomic data to the government, following the official request that such data may help in setting pharmaceutical prices. The companies have cooperated because, by doing so, they could influence pricing decisions for new products. However, the quality of these data at present is considered to be poor and heavily biased. The introduction of pharmacoeconomic guidelines that outline a set of standardised factors to be included in evaluations are necessary, so that an appropriate comparison of the cost effectiveness of the many new drugs that are introduced onto the Japanese market each year can be made. In addition to supporting the development of standardised guidelines, the Ministry of Health and Welfare should clarify how pharmacoeconomic data are to be used to aid policy decisions and also mandate the publication of pharmacoeconomic data.

本文言語English
ページ(範囲)546-551
ページ数6
ジャーナルPharmacoEconomics
10
6
DOI
出版ステータスPublished - 1996 1月 1

ASJC Scopus subject areas

  • 薬理学
  • 健康政策
  • 公衆衛生学、環境および労働衛生

フィンガープリント

「A case for the adoption of pharmacoeconomic guidelines in Japan」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル